0,1,2,3,4,5,6
Table 7.5:   Subgroup analysis of first-line immune checkpoint inhibitor combinations in RCC patients,,,,,,
Study,"N (
ITT)",Therapy,"N 
(sRCC)","PFS (mo.)
Median (95% CI) 
HR","OS (mo.)
Median (95% CI)
HR","ORR (%)
(95% CI)"
"KEYNOTE-426
NCT02853331
Median  
follow-up  
12.8 mo. [540]",861,"PEMBRO + AXI
SUN","51
54","NR
8.4 
HR: 0.54 
(0.29–1.00)","NR
NR
HR: 0.58 
(0.21–1.59)","58.8
31.5"
"JAVELIN 101 
NCT02684006
[541, 542]",886,"AVE + AXI
SUN","47
61","7.0 (5.3–13.8) 
4.0 (2.7–5.7) 
HR 0.57  
(0.33–1.00)",NA,"46.8 (32.1–61.9) 
21.3 (11.9–33.7)"
"IMmotion151
NCT02420821
Median 
follow-up 
13 to 17 mo.
[543]",915,"ATEZO + BEV
SUN","68
74","8.3 (5.4, 12.9)
5.3 (3.3, 6.7)
HR: 0.52  
(0.34–0.79)","21.7 (15.3, NE)
15.4 (10.4, 19.5)
0.64 (0.41, 1.01)","49 (36–1)
14 (7–23)"
"Checkmate 
214
NCT02231749
Median 
follow-up of 
30 mo. [544]",1096,"NIVO + IPI
SUN","60
52","8.4 (5.2–24.0)
4.9 (4.0–7.0)
HR: 0.61 
(0.38–0.97)","31.2 (23.0–NE)
13.6 (7.7–20.9)
HR: 0.55  
(0.33–0.90)","56.7 (43.2–69.4)
19.2 (9.6–32.5)"
"CheckMate 
9ER 
NCT03141177
Median 
follow-up  
16 mo. [545]",651,"NIVO + CABO
SUN","34
41","10.3 (5.6–19.4)
4.2 (2.6–8.3)
HR: 0.42 
(0.23–0.74)","NR (22.8–NE)
19.7 (8.9–29.5)
HR: 0.36 
(0.17–0.79)","55.9 (37.9–72.8)
22.0 (10.6–37.6)"
"CLEAR
NCT02811861
Median  
follow-up 
27 mo. [527, 
546]",712,"PEMBRO + LEN
SUN","28
21","11.1
5.5
HR: 0.39 
(0.18–0.84)","NE
NE
HR: 0.91 
(0.32–2.58)","60.7
23.8"
